The mission of the Vaccinology Core at LMIV is to address the global need for a malaria vaccine by focusing fundamental and clinical research in malaria immunobiology and vaccinology. BSAM2/Alhydrogel+CPG 7909, a vaccine candidate comprised of AMA1-FVO, AMA1-3D7, MSP142-FVO and MSP142-3D7 in equal mass ratio, has been evaluated in a Phase 1 trial in US. Following safety evaluation of the vaccine in US volunteers, the vaccine candidate is being evaluated in adults in a Phase 1b trial in Mali. The vaccine is well tolerated, whereas the immunogenicity and correlation between antibody titers and the in vitro growth inhibitory activities are being analyzed.
|Zhu, Daming; Huang, Shuhui; McClellan, Holly et al. (2012) Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer. Vaccine 30:189-94|
|Ellis, Ruth D; Sagara, Issaka; Doumbo, Ogobara et al. (2010) Blood stage vaccines for Plasmodium falciparum: Current status and the way forward. Hum Vaccin 6:|
|Ellis, Ruth D; Martin, Laura B; Shaffer, Donna et al. (2010) Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 5:e8787|
|Traore, Boubacar; Kone, Younoussou; Doumbo, Safiatou et al. (2009) The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 27:7299-303|
|Ellis, Ruth D; Dicko, Alassane; Sagara, Issaka et al. (2008) Short report: elevated levels of alanine aminotransferase and hepatitis A in the context of a pediatric malaria vaccine trial in a village in Mali. Am J Trop Med Hyg 79:980-2|